PAVmed Management
Management criteria checks 2/4
PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 9.92 years. total yearly compensation is $1.45M, comprised of 62.1% salary and 37.9% bonuses, including company stock and options. directly owns 4.1% of the company’s shares, worth $772.91K. The average tenure of the management team and the board of directors is 1.7 years and 9.3 years respectively.
Key information
Lishan Aklog
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 62.1% |
| CEO tenure | 9.9yrs |
| CEO ownership | 4.1% |
| Management average tenure | 1.7yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed: A True Game-Changer For Medical Device Innovation
Jun 14PAVmed forms digital health company, Veris Health
Jun 02PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device
May 26PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19PAVmed drops 14% on launch of $13.4M direct offering
Jan 06PAVmed closes additional direct offering of common stock
Dec 22Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16PAVmed offers stock for $8.9M
Dec 11PAVmed EPS beats by $0.02
Nov 17There Is Progress At PAVmed, But More Patience Is Required
Oct 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$79m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$1m | US$901k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$9m | US$583k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$1m | US$431k | -US$35m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$890k | US$431k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$772k | US$346k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$444k | US$297k | -US$10m |
Compensation vs Market: Lishan's total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.
CEO
Lishan Aklog (57 yo)
9.9yrs
Tenure
US$1,450,291
Compensation
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.9yrs | US$1.45m | 4.1% $ 772.9k | |
| President & CFO | 7.2yrs | US$1.11m | 0.55% $ 104.5k | |
| Executive VP & COO | 2.3yrs | US$1.44m | 0.20% $ 36.9k | |
| Executive VP | 1.1yrs | US$593.10k | 0.049% $ 9.3k | |
| Senior VP of Molecular Genetics & Chief Scientific Officer | 1.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 2yrs | no data | 0% $ 0 | |
| Senior VP | 1.3yrs | no data | no data | |
| Senior VP & Chief Medical Officer | 1.3yrs | no data | no data |
1.7yrs
Average Tenure
57yo
Average Age
Experienced Management: PAVM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.9yrs | US$1.45m | 4.1% $ 772.9k | |
| Independent Director | 9.3yrs | US$182.23k | 0.71% $ 133.7k | |
| Member of Medical Advisory Board | 9.5yrs | no data | no data | |
| Independent Director | 2.9yrs | US$173.60k | 0.71% $ 133.7k | |
| Independent Director | 9.3yrs | US$163.60k | 0.71% $ 133.7k | |
| Member of Medical Advisory Board | 9.5yrs | no data | no data | |
| Member of Medical Advisory Board | 9.3yrs | no data | no data | |
| Member of Medical Advisory Board | 9.3yrs | no data | no data | |
| Independent Vice Chairman | 9.6yrs | US$163.60k | 3.43% $ 647.8k | |
| Member of Medical Advisory Board | 9.5yrs | no data | no data | |
| Independent Director | 3.1yrs | US$183.60k | 0.71% $ 133.7k | |
| Member of Medical Advisory Board | 7.5yrs | no data | no data |
9.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: PAVM's board of directors are considered experienced (9.3 years average tenure).